Journal article
Safe use of livers from donors with positive hepatitis B core antibody
Liver transplantation, v 8(6), pp 556-561
Jun 2002
PMID: 12037788
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Thirty-five patients received liver transplants using liver donors who had positive test results for the hepatitis B core antibody (HBcAb). In the same time frame, 195 patients received HBcAb-negative liver donors. Mean follow up for patients receiving HBcAb-positive donors was 25 months. All patients receiving HBcAb-positive donors were monitored for recurrence of hepatitis B (HBV) with HBV DNA assays. There was no de novo HBV in recipients of HBcAb-negative grafts. In the group of patients receiving HBcAb-positive donors, 4 of 35 patients died within 3 months after transplant with no evidence of HBV recurrence at time of death. Four patients were transplanted for HBV-related disease and were postoperatively placed on lamivudine and hepatitis B immune globulin (HBIG). HBV recurrence was seen in one of these patients. Of the remaining 27 patients, three of three mismatched patients (HBcAb-positive donor to HBcAb-negative recipient) developed de novo HBV (100%). Of 24 matched patients (HBcAb-positive donor to HBcAb-positive recipient), only two (7%) developed recurrent HBV allograft reinfection. All de novo and recurrent HBV infections were successfully managed with HBIG and lamivudine therapy. Survival for this subgroup of patients receiving HBcAb-positive donors for non-HBV-related liver disease was 100%. We conclude that the judicious use of HBcAb-positive donors is reasonably safe and associated with low morbidity and mortality, with the appropriate follow-up protocols. Additionally, lamivudine use can be reserved for those cases with de novo or recurrent HBV in the liver allograft, or, selectively, as prophylaxis in those recipients patients who are naïve to HBV and receive an HBcAb-positive donor.
Metrics
Details
- Title
- Safe use of livers from donors with positive hepatitis B core antibody
- Creators
- Cosme Manzarbeitia - Einstein Medical Center PhiladelphiaDavid J Reich - Einstein Medical Center PhiladelphiaJorge A Ortiz - Einstein Medical Center PhiladelphiaKenneth D Rothstein - Einstein Medical Center PhiladelphiaVictor R Araya - Einstein Medical Center PhiladelphiaSantiago J Munoz - Einstein Medical Center Philadelphia
- Publication Details
- Liver transplantation, v 8(6), pp 556-561
- Number of pages
- 6
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Medicine (Graduate); Surgery
- Web of Science ID
- WOS:000175898300009
- Scopus ID
- 2-s2.0-0036276851
- Other Identifier
- 991021959050404721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Gastroenterology & Hepatology
- Surgery
- Transplantation